Cancer News and Research

Latest Cancer News and Research

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

US patent reinforces Ikonisys' position in digital image-analysis industry

Ikonisys, Inc., a leading provider of next-generation, cell-based diagnostic solutions, announced today that the United States Patent and Trademark Office has issued the company United States Patent No. 7,660,454 entitled “Process for identifying FISH signals.”

25 Mar 2010

NHS needs to gear up in terms of productivity, say statisticians

In an alarming new revelation, the productivity of National Health Service NHS, has dropped steadily from 2001 by 0.4% each year and a total of 3%. 2008 has seen the largest fall, 0.7% according to the Office for National Statistics, ONS.

25 Mar 2010

Women from poor backgrounds have worse breast cancer outcomes

The largest study in Europe to look at the link between socioeconomic status and survival after breast cancer has found that women from poorer backgrounds have worse outcomes and that this is only partly explained by more advanced cancer at diagnosis.

25 Mar 2010

Changing drug therapy can help breast cancer patients get full benefit of Tamoxifen

Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors (SSRIs), prescribed drugs that inhibit the effect of an important enzyme. Now researchers have developed a strategy for overcoming this problem, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today (Wednesday).

25 Mar 2010

American Lung Association in California supports efforts for quality TB care

Tuberculosis (TB) continues to be a serious public health threat in the U.S. with nearly 13,000 TB cases reported during 2008.

25 Mar 2010

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

ImmunoCellular Therapeutics announced today that Manish Singh, Ph.D., President and CEO, will be presenting at the Cancer Stem Cells Conference, a leading industry event, on Wednesday, March 24th at 2:00 p.m. eastern time.

25 Mar 2010

Colorectal cancer survivor shares her experience

For Hempstead resident Lynette Love, mother of four and grandmother of five, surviving colorectal cancer took courage, diligence and faith. Now a 3-year survivor, Love is giving the love back to the community through her participation in the Sprint for Colorectal Oncology Prevention and Education (SCOPE) run.

25 Mar 2010

Experimental vaccine can help delay IBD and colon cancer

An experimental vaccine against an abnormal protein found in some tumors has the potential to delay the onset of inflammatory bowel disease (IBD) and in turn prevent progression to colon cancer, according to researchers at the University of Pittsburgh School of Medicine.

25 Mar 2010

China’s 3rd Annual Asia Scientific Congress programs feature latest updates on cancer

In an effort to curb the cancer rates, the country has adopted evidence-based treatment guidelines and continues to strengthen a number of strategic collaborations with the National Comprehensive Cancer Network® (NCCN®) as demonstrated by several NCCN programs scheduled throughout China this spring.

25 Mar 2010

New series of filters screen compounds for drug development

The identification of compounds that could be promising candidates for drug development has become easier following research by the Walter and Eliza Hall Institute's medicinal chemistry group.

25 Mar 2010

Xifaxan drug receives FDA approval

The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease.

25 Mar 2010

Agendia brings new personalized treatment for breast cancer patients

Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes.

24 Mar 2010

CryoLife retracts share proposal offer to acquire Medafor

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has withdrawn its $2.00 per share proposal to acquire Medafor, Inc.

24 Mar 2010

Fertility remains a significant issue for majority of breast cancer patients

The use of chemotherapy and hormonal treatments in young women can have significant implications for their fertility.

24 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

InvestorSoup.com announces investment report featuring Oncothyreon

InvestorSoup.com announces an investment report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

24 Mar 2010

Patients and doctors' views on important endpoints in incurable metastatic breast cancer

Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.

24 Mar 2010

Virtual biopsy probes to detect precancerous polyps to be available soon

The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.

24 Mar 2010

Patients to discuss future of health care system at Canadian Patient Summit

More than 100 patients living with chronic medical conditions will share their solutions for ensuring that patients are part of government decisions on the future of Canada's health care system.

24 Mar 2010